About SUROVA Study

SUROVA Study: Surgery in Ovarian Cancer

We represent a Gynecologic oncology research group at Clínica Universidad de Navarra, and we are excited to introduce the SUROVA (SURgery in OVArian cancer) project. The primary goal of this initiative is to tackle a critical, unresolved question: whether primary cytoreductive surgery or neoadjuvant chemotherapy followed by interval cytoreductive surgery leads to a higher survival rate (DFS and OS) in patients with high-grade carcinoma of the ovary, fallopian tubes, and peritoneum at FIGO stage IIIB-IVB.

Currently, a lively debate exists within the scientific community regarding the most suitable procedure. We believe that many of us, who are dedicated to take care of these patients, share the same doubts about the optimal approach. Hence, we are conducting a highly controlled retrospective study using real-world data, aiming to provide evidence on the impact of neoadjuvant chemotherapy, which can significantly contribute to informed decision-making in the treatment of patients with high-grade ovarian carcinoma in our clinical practice.

While the prospective Trust Trial, with results expected in 2024, is designed to address this question, but this study is confined to patients treated in high-quality surgical hospitals. This could introduce bias in the results, as many patients may lack access to such high-level healthcare facilities. Therefore, our objective is to extend the scope of this study to real life. To achieve this, we are seeking to collect data from patients treated globally during 2018 and 2019, involving both primary and interval cytoreduction.

We hope that the results of this study will be subjected to evaluation at international meetings and published in reputable international journals. Authorship will be based on a rigorous criterion tied to the number of valid cases included in the study. Naturally, we aim to include as many authors as possible.

We strongly believe that our patients would greatly benefit from our SUROVA data. Together, we can address this critical question and provide invaluable insights.

Study diagram

Ovarian tumor